While the Health Ministry has been given a fresh start ahead of the New Year with a new leader at its helm, concerns over the efficacy of preordered COVID-19 vaccines and the discovery of a more infectious strain of the coronavirus have put Indonesia’s vaccination plan in the spotlight again.
The country has secured more than 100 million doses of Chinese firm Sinovac’s CoronaVac vaccine candidate despite the lack of efficacy data from the company or the late-stage trials being conducted in Bandung, West Java.
Efficacy, in the case of vaccine development, is the level of effectiveness that a potential vaccine shows in a controlled laboratory environment.
Last week, a Brazilian health authority said that trials of the selfsame vaccine in the South American country showed an efficacy reading between 50 and 90 percent, Reuters reported. As many as 13,000 participants…